Barclays PLC restated their equal weight rating on shares of Illumina, Inc. (NASDAQ:ILMN) in a research report sent to investors on Monday. They currently have a $145.00 price objective on the life sciences company’s stock.

A number of other research analysts have also weighed in on ILMN. Argus reaffirmed a buy rating and issued a $170.00 price objective (down from $205.00) on shares of Illumina in a research note on Friday, October 14th. Vetr raised shares of Illumina from a sell rating to a buy rating and set a $198.61 price objective on the stock in a research note on Monday, October 3rd. Citigroup Inc. raised their price objective on shares of Illumina from $175.00 to $190.00 and gave the company a buy rating in a research note on Monday, September 12th. CL King raised shares of Illumina from a neutral rating to a buy rating in a research note on Friday, January 6th. Finally, Canaccord Genuity set a $136.00 price objective on shares of Illumina and gave the company a hold rating in a research note on Friday, October 7th. Three equities research analysts have rated the stock with a sell rating, fifteen have issued a hold rating and eight have assigned a buy rating to the stock. The stock currently has a consensus rating of Hold and an average target price of $151.96.

Shares of Illumina (NASDAQ:ILMN) opened at 162.84 on Monday. The company’s 50 day moving average is $130.13 and its 200 day moving average is $150.44. Illumina has a one year low of $119.37 and a one year high of $186.88. The company has a market cap of $23.92 billion, a P/E ratio of 54.64 and a beta of 1.16.

Illumina (NASDAQ:ILMN) last issued its earnings results on Tuesday, November 1st. The life sciences company reported $0.97 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.87 by $0.10. The business had revenue of $607 million for the quarter, compared to analyst estimates of $628.06 million. Illumina had a net margin of 18.72% and a return on equity of 23.76%. Illumina’s revenue was up 10.4% on a year-over-year basis. During the same period in the prior year, the firm earned $0.80 earnings per share. On average, equities analysts predict that Illumina will post $3.32 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: “Illumina’s (ILMN) Equal Weight Rating Reiterated at Barclays PLC” was reported by Watch List News and is the sole property of of Watch List News. If you are accessing this news story on another website, it was stolen and reposted in violation of US and international trademark and copyright law. The correct version of this news story can be viewed at http://www.watchlistnews.com/illuminas-ilmn-equal-weight-rating-reiterated-at-barclays-plc/1059850.html.

In other Illumina news, Director Daniel Bradbury sold 600 shares of the business’s stock in a transaction on Monday, November 14th. The shares were sold at an average price of $136.34, for a total transaction of $81,804.00. Following the transaction, the director now directly owns 17,065 shares of the company’s stock, valued at approximately $2,326,642.10. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, EVP Omead Ostadan sold 3,000 shares of the business’s stock in a transaction on Thursday, December 8th. The shares were sold at an average price of $121.63, for a total transaction of $364,890.00. Following the transaction, the executive vice president now directly owns 52,988 shares in the company, valued at $6,444,930.44. The disclosure for this sale can be found here. 1.60% of the stock is currently owned by corporate insiders.

A number of hedge funds and other institutional investors have recently modified their holdings of ILMN. Checchi Capital Advisers LLC increased its position in shares of Illumina by 2.4% in the second quarter. Checchi Capital Advisers LLC now owns 958 shares of the life sciences company’s stock worth $134,000 after buying an additional 22 shares during the last quarter. Concert Wealth Management Inc. increased its position in shares of Illumina by 2.9% in the third quarter. Concert Wealth Management Inc. now owns 1,732 shares of the life sciences company’s stock worth $315,000 after buying an additional 48 shares during the last quarter. Mn Services Vermogensbeheer B.V. increased its position in shares of Illumina by 2.0% in the third quarter. Mn Services Vermogensbeheer B.V. now owns 3,771 shares of the life sciences company’s stock worth $685,000 after buying an additional 73 shares during the last quarter. Cullen Frost Bankers Inc. increased its position in shares of Illumina by 1.1% in the second quarter. Cullen Frost Bankers Inc. now owns 6,770 shares of the life sciences company’s stock worth $951,000 after buying an additional 75 shares during the last quarter. Finally, Halsey Associates Inc. CT increased its position in shares of Illumina by 0.7% in the second quarter. Halsey Associates Inc. CT now owns 12,510 shares of the life sciences company’s stock worth $1,756,000 after buying an additional 90 shares during the last quarter. 92.94% of the stock is currently owned by institutional investors and hedge funds.

Illumina Company Profile

Illumina, Inc (Illumina) offers sequencing and array-based solutions for genetic analysis. The Company’s products and services serve customers in a range of markets, enabling the adoption of genomic solutions in research and clinical settings. The Company’s customers include genomic research centers, academic institutions, government laboratories and hospitals, as well as pharmaceutical, biotechnology, agrigenomics and commercial molecular diagnostic laboratories, and consumer genomics companies.

5 Day Chart for NASDAQ:ILMN

Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.